{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:31:20Z","timestamp":1770222680385,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Veterinary Cardiology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jvc.2019.07.002","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T01:59:39Z","timestamp":1564019979000},"page":"7-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Use of rivaroxaban for treatment of cranial vena cava\u00a0syndrome secondary to transvenous pacemaker lead thrombosis in a dog"],"prefix":"10.1016","volume":"25","author":[{"given":"B.","family":"Lozada Miranda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Walton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.N.","family":"LeVine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Blong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Ware","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvc.2019.07.002_bib1","first-page":"701","article-title":"Cranial vena cava syndrome","volume":"24","author":"Cote","year":"2002","journal-title":"Compend Continuing Educ Pract Vet"},{"key":"10.1016\/j.jvc.2019.07.002_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jvc.2010.09.001","article-title":"Cranial vena caval syndrome secondary to central venous obstruction associated with a pacemaker lead in a dog","volume":"12","author":"Mulz","year":"2010","journal-title":"J Vet Cardiol"},{"key":"10.1016\/j.jvc.2019.07.002_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0002-8703(77)80174-9","article-title":"Cardiac pathology of transvenous pacemakers in dogs","volume":"93","author":"Fishbein","year":"1977","journal-title":"Am Heart J"},{"key":"10.1016\/j.jvc.2019.07.002_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jvc.2009.02.008","article-title":"Caudal vena cava obstruction caused by redundant pacemaker lead in a dog","volume":"11","author":"Stauthammer","year":"2009","journal-title":"J Vet Cardiol"},{"key":"10.1016\/j.jvc.2019.07.002_bib5","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/vec.12466","article-title":"The use of rivaroxaban for the treatment of thrombotic complications in four dogs","volume":"26","author":"Yang","year":"2016","journal-title":"J Vet Emerg Crit Care"},{"key":"10.1016\/j.jvc.2019.07.002_bib6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/jvim.12512","article-title":"Complication rates associated with transvenous pacemaker implantation in dogs with high-grade atrioventricular block performed during versus after normal business hours","volume":"29","author":"Ward","year":"2015","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.jvc.2019.07.002_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jvc.2008.09.001","article-title":"Cranial vena caval syndrome secondary to transvenous pacemaker implantation in two dogs","volume":"10","author":"Van De Wiele","year":"2008","journal-title":"J Vet Cardiol"},{"key":"10.1016\/j.jvc.2019.07.002_bib8","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2460\/javma.235.12.1467","article-title":"Successful treatment of pacemaker-induced stricture and thrombosis of the cranial vena cava in two dogs by use of anticoagulants and balloon venoplasty","volume":"235","author":"Cunningham","year":"2009","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.jvc.2019.07.002_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5326\/0460186","article-title":"Cranial vena caval thrombosis associated with endocardial pacing leads in three dogs","volume":"46","author":"Murray","year":"2010","journal-title":"J Am Anim Hosp Assoc"},{"key":"10.1016\/j.jvc.2019.07.002_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.thromres.2010.09.008","article-title":"The mechanism of action of rivaroxaban \u2013 an oral, direct Factor Xa inhibitor \u2013 compared with other anticoagulants","volume":"127","author":"Samama","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.jvc.2019.07.002_bib11","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jvc.2019.07.002_bib12","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1021\/jm050101d","article-title":"Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4- (3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor","volume":"48","author":"Roehrig","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.jvc.2019.07.002_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.tvjl.2013.08.001","article-title":"Rivaroxaban demonstrates in\u00a0vitro anticoagulant effects in canine plasma","volume":"198","author":"Conversy","year":"2013","journal-title":"Vet J"},{"key":"10.1016\/j.jvc.2019.07.002_bib14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/00498250500250493","article-title":"Pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - in rats and dogs","volume":"35","author":"Weinz","year":"2005","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jvc.2019.07.002_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.tvjl.2017.03.006","article-title":"Anticoagulant activity of oral rivaroxaban in healthy dogs","volume":"223","author":"Conversy","year":"2017","journal-title":"Vet J"},{"key":"10.1016\/j.jvc.2019.07.002_bib16","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/vec.12480","article-title":"Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune-mediated hemolytic anemia","volume":"26","author":"Morassi","year":"2016","journal-title":"J Vet Emerg Crit Care"},{"key":"10.1016\/j.jvc.2019.07.002_bib17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/vec.12796","article-title":"Consensus on the rational use of antithrombotics in veterinary critical Care (CURATIVE): domain 5-discontinuation of anticoagulant therapy in small animals","volume":"29","author":"Brainard","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"10.1016\/j.jvc.2019.07.002_bib18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/vec.12795","article-title":"Consensus on the rational use of antithrombotics in veterinary critical Care (CURATIVE): domain 3\u2014defining antithrombotic protocols","volume":"29","author":"Blais","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"10.1016\/j.jvc.2019.07.002_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/vec.12794","article-title":"Consensus on the rational use of antithrombotics in veterinary critical Care (CURATIVE ): domain 4 \u2014 refining and monitoring antithrombotic therapies","author":"Sharp","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"10.1016\/j.jvc.2019.07.002_bib20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1476-4431.2011.00656.x","article-title":"Examination of hemostatic parameters to detect hypercoagulability in dogs with severe protein-losing nephropathy","volume":"21","author":"Donahue","year":"2011","journal-title":"J Vet Emerg Crit Care"},{"key":"10.1016\/j.jvc.2019.07.002_bib21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/030098587100800406","article-title":"Thrombosis complicating renal amyloidosis in dogs","volume":"363","author":"Slauson","year":"1971","journal-title":"Vet Pathol"},{"key":"10.1016\/j.jvc.2019.07.002_bib22","first-page":"68","article-title":"Familial protein-losing enteropathy and protein-losing nephropahty in soft coated wheaten terriers: 222 cases","volume":"14","author":"Littman","year":"2000","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.jvc.2019.07.002_bib23","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1111\/jvim.12223","article-title":"Consensus recommendations for the diagnostic investigation of dogs with suspected glomerular disease","volume":"27","author":"Littman","year":"2013","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.jvc.2019.07.002_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/vec.12797","article-title":"Consensus on the rational use of antithrombotics in veterinary critical Care (CURATIVE): domain 1\u2014defining populations at risk","volume":"29","author":"deLaforcade","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"10.1016\/j.jvc.2019.07.002_bib25","first-page":"739","article-title":"Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: a pilot study","volume":"15","author":"Zhang","year":"2018","journal-title":"Exp Ther Med"}],"container-title":["Journal of Veterinary Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1760273419300426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1760273419300426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T16:11:59Z","timestamp":1573315919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1760273419300426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":25,"alternative-id":["S1760273419300426"],"URL":"https:\/\/doi.org\/10.1016\/j.jvc.2019.07.002","relation":{},"ISSN":["1760-2734"],"issn-type":[{"value":"1760-2734","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of rivaroxaban for treatment of cranial vena cava\u00a0syndrome secondary to transvenous pacemaker lead thrombosis in a dog","name":"articletitle","label":"Article Title"},{"value":"Journal of Veterinary Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvc.2019.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}